115 related articles for article (PubMed ID: 22407972)
1. Analysis of dose-response in flexible dose titration clinical studies.
Xu XS; Yuan M; Nandy P
Pharm Stat; 2012; 11(4):280-6. PubMed ID: 22407972
[TBL] [Abstract][Full Text] [Related]
2. The challenges of evaluating dose response in flexible-dose trials using marginal structural models.
Lipkovich I; Mallinckrodt CH; Faries DE
Pharm Stat; 2012; 11(6):485-93. PubMed ID: 23060290
[TBL] [Abstract][Full Text] [Related]
3. Assessing departure from dose linearity under a repeated measures incomplete block design.
Cheng B; Chow SC
Pharm Stat; 2011; 10(4):357-62. PubMed ID: 21104786
[TBL] [Abstract][Full Text] [Related]
4. Evaluating potential benefits of dose-exposure-response modeling for dose finding.
Hsu CH
Pharm Stat; 2009; 8(3):203-15. PubMed ID: 19629954
[TBL] [Abstract][Full Text] [Related]
5. Model-based approaches for time-dependent dose finding with repeated binary data.
Benda N
Stat Med; 2010 May; 29(10):1096-106. PubMed ID: 20082362
[TBL] [Abstract][Full Text] [Related]
6. Bayesian population modeling of phase I dose escalation studies: Gaussian process versus parametric approaches.
Russu A; Poggesi I; Gomeni R; De Nicolao G
IEEE Trans Biomed Eng; 2011 Nov; 58(11):3156-64. PubMed ID: 21846598
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
Lledó-García R; Hennig S; Karlsson MO
Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
Wang M; Day R
J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
[TBL] [Abstract][Full Text] [Related]
9. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
Paciorek CJ; Liu Y;
Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
[TBL] [Abstract][Full Text] [Related]
10. Bayesian population approaches to the analysis of dose escalation studies.
Russu A; De Nicolao G; Poggesi I; Neve M; Gomeni R
Comput Methods Programs Biomed; 2012 Aug; 107(2):189-201. PubMed ID: 21764475
[TBL] [Abstract][Full Text] [Related]
11. Adaptive modelling of dose-response relationships using smoothing splines.
Kirby S; Colman P; Morris M
Pharm Stat; 2009; 8(4):346-55. PubMed ID: 19205006
[TBL] [Abstract][Full Text] [Related]
12. Evaluating heterogeneity in indoor and outdoor air pollution using land-use regression and constrained factor analysis.
Levy JI; Clougherty JE; Baxter LK; Houseman EA; Paciorek CJ;
Res Rep Health Eff Inst; 2010 Dec; (152):5-80; discussion 81-91. PubMed ID: 21409949
[TBL] [Abstract][Full Text] [Related]
13. Testing non-inferiority and superiority for two endpoints for several treatments with a control.
Lawrence J
Pharm Stat; 2011; 10(4):318-24. PubMed ID: 20949636
[TBL] [Abstract][Full Text] [Related]
14. Impact of mis-specification of the treatment model on estimates from a marginal structural model.
Lefebvre G; Delaney JA; Platt RW
Stat Med; 2008 Aug; 27(18):3629-42. PubMed ID: 18254127
[TBL] [Abstract][Full Text] [Related]
15. Bias reduction in logistic dose-response models.
Wagler A
J Biopharm Stat; 2011 May; 21(3):405-22. PubMed ID: 21442516
[TBL] [Abstract][Full Text] [Related]
16. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationship from longitudinal data with response-dependent dose modification using likelihood methods.
Funatogawa I; Funatogawa T
Biom J; 2012 Jul; 54(4):494-506. PubMed ID: 22641310
[TBL] [Abstract][Full Text] [Related]
18. A proof-of-concept clinical trial design combined with dose-ranging exploration.
Wang X; Ting N
Pharm Stat; 2012; 11(5):403-9. PubMed ID: 22714951
[TBL] [Abstract][Full Text] [Related]
19. Optimal adaptive design in clinical drug development: a simulation example.
Maloney A; Karlsson MO; Simonsson US
J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
[TBL] [Abstract][Full Text] [Related]
20. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain.
Kowalski KG; Olson S; Remmers AE; Hutmacher MM
Clin Pharmacol Ther; 2008 Jun; 83(6):857-66. PubMed ID: 17882158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
